A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB 21447 in Patients With Mature B Cell Malignancies

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521600-21-00

Acronym

BGB-21447-101

Enrollment

Registered

2025-09-29

Start date

Unknown

Completion date

2025-12-19

Last updated

2025-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mature B-Cell malignancies

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Italy

None listed

Source: EU CTIS · Data processed: Feb 4, 2026